Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4560028 | 0.83 | GAA (0.60) | HTTLMNAGAAKDM4EHPGD | |
| SCHEMBL19884755 | 0.77 | HTT (0.55) | HTTLMNAGAAKDM4EHPGD | |
| SCHEMBL14861110 | 0.76 | HSD17B10 (0.49) | LMNAGAAKDM4EALDH1A1RAB9A | |
| SCHEMBL16083486 | 0.75 | HSD17B10 (0.53) | GAAKDM4EALDH1A1BCHE | |
| SCHEMBL31483014 | 0.74 | GAA (0.49) | LMNAGAAKDM4EALDH1A1MAPK1 | |
| SCHEMBL8139296 | 0.74 | MEN1 (0.49) | HTTLMNAGAAKDM4EALDH1A1 | |
| SCHEMBL842103 | 0.74 | HTT (0.68) | HTTLMNAGAAKDM4EALDH1A1 | |
| SCHEMBL5020904 | 0.74 | HTT (0.97) | HTTLMNAALDH1A1MAPK1PKM | |
| SCHEMBL3021250 | 0.74 | LMNA (0.56) | LMNAGAAKDM4EHPGDDUSP3 | |
| SCHEMBL17471147 | 0.74 | LMNA (0.52) | HTTLMNAGAAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240447-A2 | MORPHOLINE DERIVATES AS ANTIOBESITY AGENTS | AstraZeneca AB (Publ) (SE) | 2010-10-20 | — | — | EP | claimed |
| US-20090203695-A1 | Compounds IV | BIOVITRUM AB (SE) | 2009-08-13 | — | — | US | claimed |
| WO-2009071678-A2 | MORPHOLINE DERIVATIVES AS ANTIOBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | claimed |
| EP-2240447-A2 | MORPHOLINE DERIVATES AS ANTIOBESITY AGENTS | AstraZeneca AB (Publ) (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-20090203695-A1 | Compounds IV | BIOVITRUM AB (SE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009071678-A2 | MORPHOLINE DERIVATIVES AS ANTIOBESITY AGENTS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203695-A1 | Compounds IV | GPR119, FABP4, LIPC | HTT 3886/4885LMNA 748/4885GAA 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.